TLSI
TriSalus Life Sciences Inc

286
Mkt Cap
$237.33M
Volume
27,771.00
52W High
$7.95
52W Low
$3.42
PE Ratio
-2.36
TLSI Fundamentals
Price
$4.57
Prev Close
$4.75
Open
$4.60
50D MA
$6.23
Beta
0.42
Avg. Volume
138,642.25
EPS (Annual)
-$1.31
P/B
-8.87
Rev/Employee
$267,554.54
Loading...
Loading...
News
all
press releases
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies...
Business Wire·2h ago
News Placeholder
More News
News Placeholder
TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Lowered by Wall Street Zen
Wall Street Zen cut shares of TriSalus Life Sciences from a "hold" rating to a "sell" rating in a research note on Sunday...
MarketBeat·1d ago
News Placeholder
TriSalus Life Sciences (NASDAQ:TLSI) Upgraded at Wall Street Zen
Wall Street Zen upgraded shares of TriSalus Life Sciences from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·9d ago
News Placeholder
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Consensus Rating of "Hold" from Analysts
Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) have received a consensus recommendation of "Hold" from the five research firms that are currently covering the stock...
MarketBeat·17d ago
News Placeholder
TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Lowered by Wall Street Zen
Wall Street Zen cut shares of TriSalus Life Sciences from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·23d ago
News Placeholder
TriSalus Life Sciences, Inc. (TLSI) Upgraded to Buy: Here's What You Should Know
TriSalus Life Sciences, Inc. (TLSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·26d ago
News Placeholder
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies...
Business Wire·28d ago
News Placeholder
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Consensus Recommendation of "Hold" from Analysts
Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) have received a consensus recommendation of "Hold" from the five ratings firms that are presently covering the stock, MarketBeat...
MarketBeat·1mo ago
News Placeholder
TriSalus Life Sciences (NASDAQ:TLSI) Given New $12.00 Price Target at Canaccord Genuity Group
Canaccord Genuity Group lifted their price target on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a "buy" rating in a research note on Wednesday...
MarketBeat·2mo ago
News Placeholder
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients...
Business Wire·2mo ago
<
1
2
...
>

Latest TLSI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.